title: "Pseudoprogression" of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy.
authors.affiliation: Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Japan.
authors.forename: Kentaro
authors.initials: K
authors.lastname: Ito
authors.affiliation: Respiratory Center, Matsusaka Municipal Hospital, Matsusaka, Japan.
authors.forename: Osamu
authors.initials: O
authors.lastname: Hataji
authors.affiliation: Department of Pathology, Matsusaka Municipal Hospital, Matsusaka, Japan.
authors.forename: Koji
authors.initials: K
authors.lastname: Katsuta
authors.affiliation: Department of Pulmonary and Critical Care Medicine, Mie University Graduate School of Medicine, Tsu, Japan.
authors.forename: Tetsu
authors.initials: T
authors.lastname: Kobayashi
authors.affiliation: Department of Immunology, Mie University Graduate School of Medicine, Tsu, Japan. Electronic address: gabazza@doc.medic.mie-u.ac.jp.
authors.forename: Esteban C
authors.initials: EC
authors.lastname: Gabazza
authors.affiliation: Department of Pathology and Molecular Diagnostics, Aichi Cancer Center Hospital, Nagoya, Japan.
authors.forename: Yasushi
authors.initials: Y
authors.lastname: Yatabe
authors.affiliation: Mie University Center for Physical and Mental Health, Mie University Graduate School of Medicine, Tsu, Japan.
authors.forename: Osamu
authors.initials: O
authors.lastname: Taguchi
authors.affiliation: Third Department of Internal Medicine, Wakayama Medical University, Wakayama, Japan.
authors.forename: Nobuyuki
authors.initials: N
authors.lastname: Yamamoto
mesh_terms: D008949:Adenoma, Pleomorphic / Q000139:chemically induced / Q000473:pathology*; D000368:Aged; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D000970:Antineoplastic Agents / Q000009:adverse effects*; D002277:Carcinoma / Q000139:chemically induced / Q000473:pathology*; D018450:Disease Progression; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D000077594:Nivolumab
chemical_list: D000911:Antibodies, Monoclonal; D000970:Antineoplastic Agents; D000077594:Nivolumab